SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2016LiverMultiScan – quantitative MR imaging for NASH | Rajarshi BanerjeeView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2016O_05 - Validation of multiparametric MRI in the assessment and staging of non-alcoholic fatty liver disease | Dr. P. EddowesView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2016O_04 - Blood-based Protein Biomarkers of NASH | Dr. S. WilliamsView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2016NASH and Fibroscan | Raj Vuppalanchi, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2016Noninvasive imaging methods for assessment of liver damage in NASH | Bachir Taouli, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2016Methods of MR fat quantification and their pros and cons | Michael Middleton, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseOptimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016Management of DAA Failures - Gregory T. Everson, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseOptimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016Obstacles to Treatment: Renal Disease, Ribavirin, DDIs - Michael Charlton, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseOptimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016Post-LT Renal Failure and HCV Rx - Peter Ferenci, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseOptimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016Use of HCV+ Donor Grafts - Didier Samuel, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseOptimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016What Are the Treatment Options? - Maria Londoño, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseOptimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016Achieving SVR in CTP C – MELD Purgatory - Christophe Duvoux, MDView Slideset
